Market Closed -
Nasdaq
04:00:00 2025-06-24 pm EDT
5-day change
1st Jan Change
3.540 USD
+3.21%
+1.43%
+119.88%
Insider Trends: Insider 90-Day Selling Trend Extended at Neuronetics
Published on 07/19/2021 at 17:34,
updated on 07/19/2021 at 17:35
Neuronetics, Inc., Q1 2025 Earnings Call, May 06, 2025
Jun. 17
Neuronetics Announces Clinical Presence At The 2025 Clinical TMS Society Annual Meeting And Progress In Greenbrook's Personalized Care Trial Program
Jun. 10
RE
Neuronetics Set To Join Russell 2000® And Russell 3000® Indexes
Jun. 02
RE
Neuronetics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025
May. 06
CI
Neuronetics, Inc Announces Retirement of Steve Furlong as Chief Financial Officer, Effective March 31, 2026
May. 06
CI
Neuronetics, Inc. Revises Earnings Guidance for the Full Year 2025
May. 06
CI
Neuronetics, Inc. Provides Earnings Guidance for the Second Quarter of 2025
May. 06
CI
Neuronetics Some Non-Cash Revisions Made To Financial Statements Related To Co's Acquisition Of Greenbrook Tms & Shares Outstanding In Q4
Mar. 27
RE
Neuronetics, Inc., Q4 2024 Earnings Call, Mar 04, 2025
Mar. 04
Neuronetics, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2025
Mar. 04
CI
Neuronetics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024
Mar. 04
CI
Neuronetics Seeks Acquisitions
Feb. 07
CI
Neuronetics Prices Eight Million Share Offering at $2.25 Per Share
Feb. 07
MT
Neuronetics, Inc. Unveils Two Significant Publications on TMS Therapy for Depression
Jan. 29
CI
Neuronetics, Inc. Announces Unaudited Revenue Results for Fourth Quarter and Full Year 2024
Jan. 13
CI
Neuronetics, Inc. Provides Earnings Guidance for the Full Year 2025
Jan. 13
CI
Neuronetics, Inc. completed the acquisition of Greenbrook TMS Inc. (OTCPK:GBNH.F) from Madryn Health Partners II (Cayman Feeder), LP, fund managed by Madryn Asset Management, LP, 1315 Capital II, L.P. fund managed by 1315 Capital, LLC, Greybrook Health Inc. and others for $0.58 million.
Dec. 08
CI
Neuronetics, Inc., Q3 2024 Earnings Call, Nov 12, 2024
Nov. 12
Earnings Flash (STIM) NEURONETICS Reports Q3 Revenue $18.5M
Nov. 12
MT
Neuronetics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024
Nov. 12
CI
Neuronetics, Inc. Provides Standalone Earnings Guidance for the Fourth Quarter and Full Year 2024
Nov. 12
CI
Neuronetics, Greenbrook Receive Interim Order for Special Meeting of Shareholders for Greenbrook
24-10-04
MT
Neuronetics, Inc. Expands Health Policies Enhance Tms Therapy Access for Adolescents and Adults
24-09-19
CI
William Blair Downgrades Neuronetics to Market Perform From Outperform
24-08-13
MT
Neuronetics Shares Slump as Q2 Results Fall Below Estimates; Merger Announcement
24-08-12
MT
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
STIM: Dynamic Chart
Neuronetics, Inc. is a commercial-stage medical technology company. The Company is focused on designing, developing and marketing products for patients who suffer from neurohealth disorders. Its commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation (TMS) to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The NeuroStar Advanced Therapy System is used to treat adult patients with major depressive disorder (MDD). The Company intends to continue to pursue development of its NeuroStar Advanced Therapy System for additional indications. The Company sells its NeuroStar Advanced Therapy System and recurring treatment sessions in the United States. Its primary focus is on selling to psychiatrists, with primary care physicians and pain management specialists.
More about the company
Average target price
6.833 USD
Spread / Average Target
+93.03%
Consensus
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
Select your edition
All financial news and data tailored to specific country editions